DE60325760D1 - Kovalent an hyaluronsäure oder dessen derivate gebundene taxane - Google Patents

Kovalent an hyaluronsäure oder dessen derivate gebundene taxane

Info

Publication number
DE60325760D1
DE60325760D1 DE60325760T DE60325760T DE60325760D1 DE 60325760 D1 DE60325760 D1 DE 60325760D1 DE 60325760 T DE60325760 T DE 60325760T DE 60325760 T DE60325760 T DE 60325760T DE 60325760 D1 DE60325760 D1 DE 60325760D1
Authority
DE
Germany
Prior art keywords
hyaluronic acid
taxane
derivatives
covalent
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60325760T
Other languages
English (en)
Inventor
Luca Gilda De
Bettolo Rinaldo Marini
Luisa Maria Migneco
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fidia Farmaceutici SpA
Original Assignee
Fidia Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fidia Farmaceutici SpA filed Critical Fidia Farmaceutici SpA
Application granted granted Critical
Publication of DE60325760D1 publication Critical patent/DE60325760D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Epoxy Compounds (AREA)
DE60325760T 2002-10-18 2003-10-10 Kovalent an hyaluronsäure oder dessen derivate gebundene taxane Expired - Lifetime DE60325760D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000271A ITPD20020271A1 (it) 2002-10-18 2002-10-18 Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati.
PCT/EP2003/011239 WO2004035629A2 (en) 2002-10-18 2003-10-10 Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives

Publications (1)

Publication Number Publication Date
DE60325760D1 true DE60325760D1 (de) 2009-02-26

Family

ID=32104794

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60325760T Expired - Lifetime DE60325760D1 (de) 2002-10-18 2003-10-10 Kovalent an hyaluronsäure oder dessen derivate gebundene taxane

Country Status (23)

Country Link
US (2) US7897584B2 (de)
EP (2) EP2045270B1 (de)
JP (1) JP4704753B2 (de)
KR (1) KR101076414B1 (de)
CN (1) CN1705683B (de)
AT (1) ATE420117T1 (de)
AU (1) AU2003267441B2 (de)
BR (1) BR0315431A (de)
CA (2) CA2502531C (de)
DE (1) DE60325760D1 (de)
DK (1) DK1560854T3 (de)
ES (2) ES2320439T3 (de)
HK (1) HK1082753A1 (de)
HR (1) HRP20050416B1 (de)
IL (1) IL168086A (de)
IT (1) ITPD20020271A1 (de)
NO (1) NO333042B1 (de)
NZ (2) NZ547668A (de)
PL (2) PL376349A1 (de)
PT (1) PT1560854E (de)
RU (1) RU2384593C2 (de)
SI (1) SI1560854T1 (de)
WO (1) WO2004035629A2 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7923431B2 (en) 2001-12-21 2011-04-12 Ferrosan Medical Devices A/S Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis
EP2286795B1 (de) * 2002-06-26 2016-10-26 SynCore Biotechnology CO., LTD Herstellungsmethode von diagnostischen und therapeutischen Stoffen in einen kationischen Trägersystem
KR20070046093A (ko) 2004-07-09 2007-05-02 훼로산 아크티에 셀스카브 히알루론산을 포함하는 지혈 조성물
WO2007004675A1 (ja) * 2005-07-06 2007-01-11 Seikagaku Corporation 薬剤導入光架橋ヒアルロン酸誘導体ゲル
ITPD20050242A1 (it) * 2005-08-03 2007-02-04 Fidia Farmaceutici Bioconiugati antitumorali dell'acido ialuronico o dei suoi derivati, ottenibili per coniugazione chimica diretta o indiretta, e loro impiego in campo farmaceutico
EP1973952A4 (de) * 2006-01-23 2010-09-01 Kwangju Inst Sci & Tech Konjugat, umfassend eine kovalent an ein mucoadhäsives polymer gebundene pharmazeutisch wirksame verbindung, und transmucosale verabreichungsmethode für eine pharmazeutisch wirksame verbindung unter anwendung davon
IE20060049A1 (en) * 2006-01-25 2007-08-08 Eurand Pharmaceuticals Ltd A novel drug delivery system: use of hyaluronic acid as a carrier moleclue for different classes of therapeutic active agents
CN101501075B (zh) * 2006-08-04 2013-07-10 诺维信生物制药丹麦公司 支化透明质酸和制造方法
WO2008089256A2 (en) * 2007-01-16 2008-07-24 Cappella, Inc. Polymeric therapeutics
ITMI20071267A1 (it) * 2007-06-22 2008-12-23 Fidia Farmaceutici Uso di coniugati dell'acido ialuronico nel trattamento locale di malattie cutanee iperproliferative
ITMI20071341A1 (it) 2007-07-05 2009-01-06 Fidia Farmaceutici Derivati di acido ialuronico contenenti gruppi in grado di rilasciare no
IE20070900A1 (en) * 2007-12-12 2009-06-24 Eurand Pharmaceuticals Ltd New anticancer conjugates
CA2713813C (en) * 2008-01-30 2017-12-05 University Of Kansas Intralymphatic chemotherapy drug carriers
EP2259803B2 (de) 2008-02-29 2019-03-13 Ferrosan Medical Devices A/S Vorrichtung zur förderung von hämostase und/oder wundheilung
US9687559B2 (en) 2008-03-19 2017-06-27 The Board Of Regents Of The University Of Oklahoma Heparosan polymers and methods of making and using same for the enhancement of therapeutics
US9925209B2 (en) 2008-03-19 2018-03-27 The Board Of Regents Of The University Of Oklahoma Heparosan-polypeptide and heparosan-polynucleotide drug conjugates and methods of making and using same
KR101584384B1 (ko) 2008-04-22 2016-01-12 피디아 파마슈티치 에스.피.에이. 종양 형성의 치료에서 히알루론산에 결합된 항종양 약물을 포함하는 신규한 제약학적 조제물의 치료적 용도
IT1391006B1 (it) * 2008-10-08 2011-10-27 Fidia Farmaceutici Uso terapeutico di nuove preparazioni farmaceutiche contenenti farmaci antitumorali legati all'acido ialuronico nel trattamento delle neoplasie
WO2010030342A2 (en) * 2008-09-09 2010-03-18 The Board Of Regents Of The University Of Oklahoma Heparosan polymers and methods of making and using same for the enhancement of therapeutics
WO2010053140A1 (ja) 2008-11-05 2010-05-14 国立大学法人 東京医科歯科大学 ヒアルロン酸誘導体、およびその医薬組成物
IT1397247B1 (it) * 2009-05-14 2013-01-04 Fidia Farmaceutici Nuovi agenti regolatori dell'attivita' citochinica
IT1399351B1 (it) * 2009-06-16 2013-04-16 Fidia Farmaceutici Procedimento per la sintesi di coniugati di glicosamminoglicani (gag) con molecole biologicamente attive, coniugati polimerici e usi relativi
KR20110032561A (ko) * 2009-09-23 2011-03-30 포항공과대학교 산학협력단 약물 전달체의 표적 특이성 조절 방법, 표적 특이적 약물 전달체, 및 표적-비특이적 약효 장기 지속성 약물 전달체
US8722644B2 (en) 2010-01-04 2014-05-13 Holy Stone Healthcare Co., Ltd. Mixture of hyaluronic acid for treating and preventing peptic ulcer and duodenal ulcer
WO2012086857A1 (ko) * 2010-12-21 2012-06-28 (주)파낙스이엠 광역학 진단 또는 치료를 위한 결합체 및 이의 제조방법
IN2014DN08122A (de) 2012-03-06 2015-05-01 Ferrosan Medical Devices As
JP6104232B2 (ja) * 2012-03-27 2017-03-29 テルモ株式会社 コーティング組成物および医療機器
EP2977066A3 (de) 2012-06-12 2016-07-27 Ferrosan Medical Devices A/S Trockene blutstillende zusammensetzung
BR112015004501B1 (pt) 2012-09-05 2021-04-13 Chugai Seiyaku Kabushiki Kaisha Derivado de ácido hialurônico tendo aminoácidos e grupos esterila introduzidos no mesmo e composição farmacêutica que o compreende
US9635795B2 (en) 2012-10-23 2017-04-25 International Business Machines Corporation Multiple expansion card insertion and extraction tool
CN103641925B (zh) * 2012-11-27 2016-08-17 王晖 水溶性多聚糖与紫杉烷类化合物的共价聚化合物，其制备方法及医药用途
BR112015030612B1 (pt) 2013-06-21 2020-07-21 Ferrosan Medical Devices A/S método para preparar uma composição seca
JP6453214B2 (ja) * 2013-07-10 2019-01-16 生化学工業株式会社 グリコサミノグリカン誘導体及びその製造方法
US10675354B2 (en) 2013-07-10 2020-06-09 Seikagaku Corporation Glycosaminoglycan derivative and method for producing same
EP3079731B1 (de) 2013-12-11 2018-08-08 Ferrosan Medical Devices A/S Trockenzusammensetzung mit extrusionsverstärker
CN103861116A (zh) * 2014-03-06 2014-06-18 沈阳药大制剂新技术有限公司 一种抗肿瘤药物的前体药物及其制备和应用
KR102394087B1 (ko) * 2014-07-31 2022-05-03 콘시글리오 나치오날레 델레 리체르체 히알루론산 및 카르노신으로부터 수득된 유도체
CN104198707B (zh) * 2014-09-12 2016-09-14 范飞舟 N-乙酰氨基葡萄糖在制备检测肿瘤的试剂盒中的应用
US11046818B2 (en) 2014-10-13 2021-06-29 Ferrosan Medical Devices A/S Dry composition for use in haemostasis and wound healing
CN104491875A (zh) * 2014-12-22 2015-04-08 中国药科大学 一种基于透明质酸-难溶性药物前药的自聚纳米系统的制备方法
CN107206165B (zh) 2014-12-24 2020-10-23 弗罗桑医疗设备公司 用于保持并混合第一和第二物质的注射器
EP3243841B1 (de) * 2015-01-09 2020-09-30 Seikagaku Corporation Chondroitinschwefelsäurederivat und arzneimittel zur behandlung von blasenerkrankungen
KR20180014042A (ko) * 2015-05-29 2018-02-07 알바트로스 테크놀로지스 리미티드 약물을 전달하기 위한 가교된 히알루론산 및 이를 이용한 약학적 제제
US10918796B2 (en) 2015-07-03 2021-02-16 Ferrosan Medical Devices A/S Syringe for mixing two components and for retaining a vacuum in a storage condition
CN108178803B (zh) * 2017-09-25 2020-03-10 温州医科大学 一种载药的肉桂醛-葡聚糖聚合物自组装纳米粒的制备及其抗肿瘤应用
EP3712181B1 (de) 2017-11-15 2022-10-26 Chugai Seiyaku Kabushiki Kaisha Mit polyethylenglykol modifiziertes hyaluronsäurederivat
CN108219029A (zh) * 2018-03-22 2018-06-29 盐城师范学院 一种水溶性卡巴他赛抗癌药物的制备方法
CN108467439A (zh) * 2018-03-22 2018-08-31 盐城师范学院 一种水溶性紫杉醇抗癌药物的制备方法
KR20210008479A (ko) 2018-05-09 2021-01-22 훼로산 메디칼 디바이스 에이/에스 지혈 조성물을 제조하는 방법
US20210228530A1 (en) * 2018-06-20 2021-07-29 Santolecan Pharmaceuticals Llc Taxane-lipid-polysaccharide dual conjugates, preparation methods thereof and uses thereof
IT201800009731A1 (it) * 2018-10-25 2020-04-25 Fidia Farm Spa Coniugato paclitaxel - acido ialuronico nel trattamento del carcinoma vescicale non infiltrante
CN111588914A (zh) * 2019-12-31 2020-08-28 辽宁垠艺生物科技股份有限公司 介入或植入医疗器械的药物涂层及其制备方法
IT202000007747A1 (it) 2020-04-10 2021-10-10 Fidia Farm Spa Coniugato acido ialuronico-paclitaxel nel trattamento del mesotelioma
IT202000008209A1 (it) * 2020-04-17 2021-10-17 Fidia Farm Spa Procedimento di sintesi di un coniugato acido ialuronico-paclitaxel
CN111892668B (zh) * 2020-07-03 2022-07-12 广东工业大学 一种化合物及其制备方法、荧光探针和抗肿瘤药物
IL297377A (en) * 2020-07-15 2022-12-01 Coval Biopharma Shanghai Co Ltd Drug administration system for local administration of therapeutic substances and its uses
CN114870031B (zh) * 2022-05-20 2023-07-07 四川大学 一种cd44靶向的紫杉烷类纳米晶体及其制备方法与应用
WO2024038088A1 (en) * 2022-08-16 2024-02-22 Synartro Ab Liquid formulations

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851521A (en) * 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
GB8713662D0 (en) * 1987-06-11 1987-07-15 Skandigen Ab Hyaluronic acid derivatives
IT1219587B (it) 1988-05-13 1990-05-18 Fidia Farmaceutici Polisaccaridi carbossiilici autoreticolati
US5356883A (en) * 1989-08-01 1994-10-18 Research Foundation Of State University Of N.Y. Water-insoluble derivatives of hyaluronic acid and their methods of preparation and use
EP0506976B1 (de) * 1990-10-18 1997-04-09 Shiseido Company Limited Kombination von hyaluronsäure mit einem medizinischen bestandteil, und seine herstellung
JP2604930B2 (ja) * 1990-12-14 1997-04-30 株式会社ディ・ディ・エス研究所 ヒアルロン酸およびコンドロイチン誘導体
WO1993024476A1 (en) * 1992-06-04 1993-12-09 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
DE69425464T2 (de) * 1993-02-26 2001-05-23 Drug Delivery System Institute, Ltd. Polysaccharidderivat und wirkstoffträger
US5616568A (en) 1993-11-30 1997-04-01 The Research Foundation Of State University Of New York Functionalized derivatives of hyaluronic acid
ITPD940054A1 (it) 1994-03-23 1995-09-23 Fidia Advanced Biopolymers Srl Polisaccaridi solfatati
BR9710646A (pt) * 1996-03-12 2000-01-11 Pg Txl Co Lp Pródrogas de paclitaxel solúveis em água.
CA2175282A1 (en) 1996-04-29 1997-10-30 Rudolf Edgar Falk Use of forms of hyaluronic acid (ha) for the treatment of cancer
CA2208924A1 (en) 1997-07-09 1999-01-09 Hyal Pharmaceutical Corporation Sparing paclitaxel by the use of hyaluronan
EP1082963A4 (de) * 1998-05-20 2004-03-17 Chugai Pharmaceutical Co Ltd Arzneimittel für hyaluronsäure-assozierte gelenkkrankheiten
ITPD980169A1 (it) * 1998-07-06 2000-01-06 Fidia Advanced Biopolymers Srl Ammidi dell'acido ialuronico e dei suoi derivati e processo per la loro preparazione.
JP2002523407A (ja) 1998-08-21 2002-07-30 ファルマヘミー ベー．フェー． パクリタキセルの水溶性類似体およびプロドラッグ
CN100374163C (zh) 1999-01-13 2008-03-12 阿尔凯米亚肿瘤学私人有限公司 增强药物功效的组合物
JP2001081103A (ja) * 1999-09-13 2001-03-27 Denki Kagaku Kogyo Kk ヒアルロン酸結合薬剤
US6593308B2 (en) 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
WO2001047561A1 (en) 1999-12-28 2001-07-05 Bioniche Life Sciences Inc. Hyaluronic acid in the treatment of cancer
IT1317358B1 (it) 2000-08-31 2003-06-16 Fidia Advanced Biopolymers Srl Derivati cross-linkati dell'acido ialuronico.
IT1317359B1 (it) 2000-08-31 2003-06-16 Fidia Advanced Biopolymers Srl Polisaccaridi percarbossilati, quali l'acido ialuronico, processo perla loro preparazione e loro impiego in campo farmaceutico e

Also Published As

Publication number Publication date
WO2004035629A2 (en) 2004-04-29
NO20052399D0 (no) 2005-05-18
EP2045270B1 (de) 2015-05-06
AU2003267441A1 (en) 2004-05-04
WO2004035629A8 (en) 2005-06-09
CN1705683A (zh) 2005-12-07
ES2320439T3 (es) 2009-05-22
US20060116346A1 (en) 2006-06-01
CA2502531A1 (en) 2004-04-29
BR0315431A (pt) 2005-08-16
DK1560854T3 (da) 2009-04-20
US20110159052A1 (en) 2011-06-30
US8034795B2 (en) 2011-10-11
PT1560854E (pt) 2009-04-15
PL392566A1 (pl) 2010-11-22
NZ540034A (en) 2007-11-30
JP2006504747A (ja) 2006-02-09
NZ547668A (en) 2008-04-30
US7897584B2 (en) 2011-03-01
HRP20050416B1 (hr) 2013-09-30
NO20052399L (no) 2005-05-18
CN1705683B (zh) 2010-04-28
JP4704753B2 (ja) 2011-06-22
ATE420117T1 (de) 2009-01-15
WO2004035629A9 (en) 2005-07-07
NO333042B1 (no) 2013-02-18
WO2004035629A3 (en) 2004-06-24
ITPD20020271A1 (it) 2004-04-19
PL216861B1 (pl) 2014-05-30
IL168086A (en) 2010-11-30
KR20050065595A (ko) 2005-06-29
ES2544481T3 (es) 2015-08-31
EP1560854B1 (de) 2009-01-07
EP1560854A2 (de) 2005-08-10
EP2045270A2 (de) 2009-04-08
AU2003267441B2 (en) 2010-01-14
RU2384593C2 (ru) 2010-03-20
SI1560854T1 (sl) 2009-06-30
EP2045270A3 (de) 2009-06-03
CA2502531C (en) 2012-10-02
PL376349A1 (en) 2005-12-27
CA2783175C (en) 2013-12-24
KR101076414B1 (ko) 2011-10-25
RU2005115116A (ru) 2006-01-20
HRP20050416A2 (en) 2006-02-28
CA2783175A1 (en) 2004-04-29
HK1082753A1 (en) 2006-06-16

Similar Documents

Publication Publication Date Title
DE60325760D1 (de) Kovalent an hyaluronsäure oder dessen derivate gebundene taxane
RS20080167A (en) Novel improved compositions for cancer therapy
CY1117326T1 (el) Παραγωγο κατεχολαμινης χρησιμο για τη θεραπεια ασθενειας parkinson
EA201001143A1 (ru) Активаторы прокаспаз "исполнителей" 3, 6 и 7
DE60031268D1 (de) Verfahren und zusammansetzung zur behandlung von krebs
CY1116156T1 (el) Παραγωγα πυριμιδινης συνδεδεμενα με οξυγονο
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
TW200724537A (en) Pyrimidine derivatives for treatment of hyperproliferative disorders
MY140840A (en) Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
CY1111547T1 (el) Συνδυασμος zd6474 και πεμετρεξεδης
EP2061456A4 (de) Zusammensetzungen und verfahren zur hemmung von cytochrom p450
EP1503748A4 (de) Arzneimittel zur linderung durch taxan induzierte neurotoxizität
CY1111899T1 (el) Καινοφανη παραγωγα πυρρολης με δραστηριοτητα αναστολεα της απακετυλασης της ιστονης
NO20064754L (no) Kombinasjonsterapi
NO20076657L (no) Kombinasjonsterapi av cancer med AZD2171 og gemcitabin
EA201070193A1 (ru) Лечение детских опухолей
LV15575A (lv) Selenofēnhromēnu deiterēti analogi, to iegūšana un izmantošana
GB2430365B (en) High-purity texaphyrin metal complexes
ATE490955T1 (de) Derivate von 4-demethylpenclomedin sowie ihre verwendung und herstellung
ATE531766T1 (de) Hochreine texaphyrinmetallkomplexe
ATE455121T1 (de) Herstellungsverfahren von derivate von bisphosphonaten
SE0203536D0 (sv) Use of a known substance for the treament of cancer and bacterial and fungal infections
ATE293107T1 (de) Luminacine analoge und deren verwendung
TNSN08171A1 (en) Pharmaceutical composition comprising at least one anticancer drug and at least one polymer

Legal Events

Date Code Title Description
8364 No opposition during term of opposition